6^th Edition of International Conference on Clinical Oncology

Dr. Reema Al Hayek is a Consultant Pediatric Oncology-Hematology and Stem Cell Transplant. She obtained her bachelor degree in Medicine, (June 1983), she was board certified in Pediatrics (Dec. 1987), Assistant Professor in General Pediatrics (Feb. 1988), Board Certified (DISC) in Pediatric Oncology Sub-Specialty at University of Rene Descartes Paris (June 1991). She obtained as well many other certifications as for the Diploma of Oncologic Pharmacology from the University of Lariboisier, St. Louis, Paris (June 1991), the Diploma in Experimental Hematology (Transfection of Genes and Trans-genesis, and Genotherapy) from the University of Rene Descartes, Paris (June 1991). She obtained the degree of Assistant Professor in Pediatric Oncology University of Paris South (June 1991) and her Executive Master in Health Administration Science in December 2013 During her working years she was assigned to the following administrative positions; Director of Medical Services at KFSHD (2015-now), Director Oncology Center, KFSHD (2010-2015), Founder and Chairwoman of the Pediatric Oncology - Hematology Department, KFSHD ( 2006-2010), Founder and Chairwoman of the department of Pediatric, KFSHD( 2005-2006). She was the Director of the Pediatric Residency Training Program from 1995 for 10 consecutive years and currently is an active member of the fellowship program for the Pediatric Hematology Oncology During her past 25 years of Clinical Experience she has developed a high expertise in Pediatric Oncology Solid Tumors, Benign Hematology and Leukemia, her field of interest in Researches is in the Hodgkin Disease and its specificity in Saudi Arabia mainly in the Eastern Province through an ongoing Epidemiological Study, other fields of interest is in the leukemia and its treatment response and genetic characteristic in Saudi Arabia multicenter study has been published. Monoclonal Target Therapy mainly in refractory or in relapsing Leukemia and in Chemotherapy Resistant Hodgkin Lymphoma and Multidrug Resistance in Acute Lymphoblastic Leukemia. Dr. Al Hayek is an active member in the following societies: member of the Pediatric Saudi Association SAPHOS (2000 till now), member of the Regional Pediatric Oncology–Hematology MECCA Group (2000 till now), member of Sanad Scientific Committee for the National Pediatric Oncology Hematology Research Grant Allocation, member of the Organizing Committee for Sanad Annual National Symposium for Pediatric Hematology Oncology, member of the International Society of Pediatric Oncology SIOP (since 1997), member of the Franco – Arab Society of Cancer (since 1991), member of Pediatric Oncology Society of the Developing Country Group PODC (since 1997), member of Pediatric Society of Oncology, Asian Group (since 1997), member of French Society of Pediatric Oncology, SFOP (since 1991), member of Children Oncology Group COG of United States (since 2008 till 2016), Founding Member in Poem Association of the Mediterranean, Regional and Gulf Group (Nov.2013)

Hodgkin Disease and its specificity, leukemia and its treatment response and genetic characteristic

Prof. Dr. Alireza Heidari, Ph.D., D.Sc. is a Full Professor and Academic Tenure of Chemistry at California South University (CSU), Irvine, California, USA. He has got his Ph.D. and D.Sc. degrees from California South University (CSU), Irvine, California, USA. Furthermore, he has double postdocs in Project Management, Oncology, Human Cancer Tissues and Synchrotron Radiation from Monash University, Melbourne, Victoria, Australia and also in Nanochemistry and Modern Molecular Electronic–Structure Computations Theory from California South University (CSU), Irvine, California, USA. His research interests include Biophysical Chemistry, Biomolecular Spectroscopy, Quantum Chemistry, Nanochemistry, Modern Electronic Structure Computations, Theoretical Chemistry, Mathematical Chemistry, Computational Chemistry, Vibrational Spectroscopy, Molecular Modelling, Ab initio & Density Functional Methods, Molecular Structure, Biochemistry, Molecular Simulation, Pharmaceutical Chemistry, Medicinal Chemistry, Oncology, Synchrotron Radiation, Synchrocyclotron Radiation, LASER, Anti–Cancer Nano Drugs, Nano Drugs Delivery, ATR–FTIR Spectroscopy, Raman Spectroscopy, Intelligent Molecules, Molecular Dynamics, Biosensors, Biomarkers, Molecular Diagnostics, Numerical Chemistry, Nucleic Acids, DNA/RNA Monitoring, DNA/RNA Hypermethylation & Hypomethylation, Human Cancer Tissues, Human Cancer Cells, Tumors, Cancer Tissues, Cancer Cells, etc. He has participated at more than three hundreds reputed international conferences, seminars, congresses, symposiums and forums around the world as yet. Also, he possesses many published articles in Science Citation Index (SCI)/International Scientific Indexing (ISI) Journals. It should be noted that he has visited many universities or scientific and academic research institutes in different countries such as United States, United Kingdom, Canada, Australia, New Zealand, Scotland, Ireland, Netherlands, Belgium, Denmark, Greece, Russia, Estonia, Ukraine, Turkey, France, Swiss, Germany, Sweden, Norway, Italy, Austria, Czech Republic, Hungary, Poland, South Africa, Egypt, Brazil, Spain, Portugal, Mexico, Japan, Singapore, Malaysia, Thailand, Taiwan, Hong Kong, South Korea, China, India, Qatar, United Arab Emirates, etc. as research fellow, sabbatical and volunteer researcher or visitor and so on heretofore. He has a history of several years of teaching for college students and various disciplines and trends in different universities. Moreover, he has been a senior advisor in various industry and factories. He is expert in many computer programs and programming languages. Hitherto, he has authored more than twenty books and book chapters in different fields of Chemistry. Syne, he has been awarded more than nine hundreds reputed international awards, prizes, scholarships and honors. Heretofore, he has multiple editorial duties in many reputed international journals, books and publishers. Hitherward, he is a member of more than three hundreds reputed international academic–scientific–research institutes around the world. It should be noted that he is currently the President of American International Standards Institute (AISI), Irvine, California, USA and also Director of the BioSpectroscopy Core Research Laboratory at California South University (CSU), Irvine, California, USA.

Oncology, Human Cancer Tissues and Synchrotron Radiation,Biophysical Chemistry, Biomolecular Spectroscopy, Quantum Chemistry, Nanochemistry, Modern Electronic Structure Computations, Theoretical Chemistry, Mathematical Chemistry, Computational Chemistry, Vibrational Spectroscopy, Molecular Modelling, Ab initio & Density Functional Methods, Molecular Structure, Biochemistry, Molecular Simulation, Pharmaceutical Chemistry, Medicinal Chemistry, Oncology, Synchrotron Radiation, Synchrocyclotron Radiation, LASER, Anti–Cancer Nano Drugs, Nano Drugs Delivery, ATR–FTIR Spectroscopy, Raman Spectroscopy, Intelligent Molecules, Molecular Dynamics, Biosensors, Biomarkers, Molecular Diagnostics, Numerical Chemistry, Nucleic Acids, DNA/RNA Monitoring, DNA/RNA Hypermethylation & Hypomethylation, Human Cancer Tissues, Human Cancer Cells, Tumors, Cancer Tissues, Cancer Cells.

Kenji Suzuki, Ph.D. (by Published Work; Nagoya University) worked at Hitachi Medical Corporation, Japan, Aichi Prefectural University, Japan, as a faculty member, and in Department of Radiology, University of Chicago, as Assistant Professor. In 2014, he joined Department of Electric and Computer Engineering and Medical Imaging Research Center, Illinois Institute of Technology, as Associate Professor. Since 2017, he has been jointly appointed in World Research Hub Initiative at Tokyo Institute of Technology, Japan, as Full Professor (Specially Appointed). He published more than 320 papers (including 110 peer-reviewed journal papers). He is inventor on 30 patents (including 13 granted patents), which were licensed to several companies and commercialized. He published 11 books and 22 book chapters, and edited 13 journal special issues. He was awarded/co-awarded more than 25 grants as PI including NIH R01 and ACS. He served as the Editor of a number of leading international journals, including Pattern Recognition and Medical Physics. He served as a referee for 91 international journals, an organizer of 62 international conferences, and a program committee member of 170 international conferences. He received 26 awards.

Pattern Recognition and Medical Physics

Dr. Boothman grew up in Detroit, Michigan, and earned his B.S. at the University of Michigan-Ann Arbor. He did his graduate work in microbiology and immunology at the University of Miami Medical School, where he received his Ph.D. under the mentorship of Dr. Sheldon Greer. His research focused on the biochemistry and pharmacology of anticancer drugs, specifically 5-fluoro-deoxycytidine derivatives. He did postdoctoral research at the Dana-Farber Cancer Institute of Harvard Medical School with Dr. Arthur B. Pardee. There, he investigated changes in several aspects of cancer cells before and after cell stress: cell cycle checkpoint regulation, molecular biology, and gene expression. His studies on β-lapachone as a radiosensitizer and DNA repair inhibitor began at this time. Dr. Boothman also discovered and cloned the first proteins and transcripts induced by ionizing radiation (IR).

Hematology-Oncology

David I Smith received his B.S. In Mathematics and Molecular Biology from the University of Wisconsin in Madison. He then went on to get his Ph.D. In Biochemistry, also at the UW Madison in 1978. His first faculty position was at Wayne State University in Detroit. For the past 22 years he has been a Professor in the Department of Laboratory Medicine and Pathology at the Mayo Clinic. He is also the Chairman of the Technology Assessment Group for the Mayo Clinic Center for Individualized Medicine. His laboratory studies genome inability and the common fragile sites and their role in cancer development. His laboratory also studies the different ways the human papillomavirus is involved in the development of different cancers. The tools that Dr. Smith’s laboratory uses to address these questions is massively parallel next generation sequencing.

Current Projects :- Oropharyngeal cancer, Long noncoding RNA.

Prof. Tao obtained his PhD from the University of Hong Kong and did his postdoc training in Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine. He was appointed as Assistant Professor in Johns Hopkins School of Medicine in 1999, and later Associate Professor and Full Professor (2008) in the Chinese University of Hong Kong. He leads the Cancer Epigenetics Laboratory in the State Key Laboratory of Oncology in South China, Faculty of Medicine, The Chinese University of Hong Kong. Prof Tao’s group has established the CpG methylomes of common tumors in Hong Kong including nasopharyngeal, esophageal, lung, digestive cancers and lymphomas; identified multiple novel TSGs (e.g. PCDH10, RASAL1, ZNF382, BLU, ZNF545, BCL6B, JPH3, DLEC1, etc) and characterized their molecular functions in cell signaling and tumorigenesis; and also developed promising epigenetic biomarkers and therapeutics. He has published 160 papers (total citations: 8500; h-index: 55) on cancer epigenetics and cancer biology in international journals, including PNAS, Lancet, JCO, Cancer Res, Blood, Gut, Hepatology and Theranostics, and 4 book chapters on epigenetics. He is an external reviewer for multiple scientific journals and an academic Editor for several journals. He also serves as a grant review panel member for China Natural Science Foundation (NSFC) and a reviewer for several other agents including AICR, Wellcome Trust, MRC/UK, Dutch Cancer Society, Singapore National Medical Research Council, and China Ministry of Science and Technology (MOST). He has been a vice-President for the international Epigenetics Society (http://epigeneticssocietyint.com/) since 2008.

Cancer epigenomics: identification of novel tumor suppressor genes (TSG) and their functional/mechanistic characterization in tumorigenesis ; Identification of epigenetic modifier genes involved in aberrant CpG methylation and chromatin-remodeling in tumors; Development of epigenetic biomarkers and epigenetic therapeutics; Epigenetic regulation of EBV genes and EBV-modulated aberrant epigenetic programming in EBV pathogenesis